The Report is produced in Chinese only.

  14-10-2019 (星期一) 國家政策支持體育行業 具備品牌的本土體育用品股料受惠
  30-09-2019 (星期一) 集采擴圍降價顯著,藥企結構性分化加快
  16-09-2019 (星期一) 科技部公佈國家新一代人工智慧創新發展試驗區建設工作指引,人工智慧相關產業將受益
  02-09-2019 (星期一) 中國嬰幼兒配方奶粉市場增長放緩,高端及超高端料成為增長動力
  19-08-2019 (星期一) 擴大醫療器械註冊人制度試點,國內醫療器械龍頭將受惠
[第1頁 / 共54頁]

國家政策支持體育行業 具備品牌的本土體育用品股料受惠

國家政策支持中國體育行業的發展,繼國務院總理李克強在國務院常務會議上,確定進一步促進體育健身和體育消費的措施後, 國務院辦公廳近日印發《體育強國建設綱要》提出一系列的戰略任務,2035年目標成為國民經濟支柱性產業,經常參與體育鍛煉人數比例達45%以上,2050年成為體育強國,人民身體素養和健康水平、體育綜合實力和國際影響力居於世界前列。



撰稿: 顧慧宇研究分析員
+852 2277 6516

This report is produced and is being distributed in Hong Kong by Phillip Securities Group with the Securities and Futures Commission (“SFC”) licence under Phillip Securities (HK) LTD and/ or Phillip Commodities (HK) LTD (“Phillip”). Information contained herein is based on sources that Phillip believed to be accurate. Phillip does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The information is for informative purposes only and is not intended to or create/induce the creation of any binding legal relations. The information provided do not constitute investment advice, solicitation, purchase or sell any investment product(s). Investments are subject to investment risks including possible loss of the principal amount invested. You should refer to your Financial Advisor for investment advice based on your investment experience, financial situation, any of your particular needs and risk preference. For details of different product's risks, please visit the Risk Disclosures Statement on Phillip (or employees) may have positions/ interests in relevant investment products. Phillip (or one of its affiliates) may from time to time provide services for, or solicit services or other business from, any company mentioned in this report. The above information is owned by Phillip and protected by copyright and intellectual property Laws. It may not be reproduced, distributed or published for any purpose without prior written consent from Phillip.
Top of Page
Contact Us
Please contact your account executive or call us now.
Research Department
Tel : (852) 2277 6846
Fax : (852) 2277 6565
Email :

Enquiry & Support
The Complaint Procedures
Louis Talk
Investor Notes
Free Subscribe
Contact Us